A massive umbrella study published in the British Medical Journal
has concluded that moderate coffee intake is generally safe for most of the population. The review examined over 200 meta-studies on the health effects of coffee consumption and concluded that three to five cups a day looks to be the safest maximum volume one should consume.
The rise of meta-analyses allowed scientists to take the data from scores of prior studies on a single topic and draw more comprehensive conclusions. In regards to coffee, many new studies started to account for more lifestyle factors, such as smoking and obesity. By 2017 there are literally hundreds of different coffee consumption studies examining links between the drink and a variety of different health outcomes. At the same time, there are dozens of meta-studies bringing all this data together.
The latest umbrella review gathers data from 218 different meta-analyses that examined over 60 different health outcomes.
Across almost all health outcomes reviewed, coffee consumption was found to either not increase risk or actually decrease risk to negative health outcomes. From diabetes and cirrhosis, to most cancers and cardiovascular disease, coffee consumption was seen to be generally safe with occasional mild benefits. The ideal intake found by the umbrella review was equal to or less than 400 mg of caffeine per day, or essentially no more than four to five standard cups.
The only two significant population subgroups noted by the study that showed a correlation between coffee consumption and negative effects were pregnant women, and women with high risks of bone fractures. During pregnancy coffee consumption was potentially associated with low birth weight and preterm birth.
For products with caffeine, check out our Mocca gummies at https://seattlegummy.com/product/mocca-box/
, in which each gummy provides the equivalent of one cup of coffee worth of caffeine.
Thanks for reading.
: Poole, R.; Roderick, P. and Hayes, P.C., Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes, British Medical Journal
, 2017; 359 doi: https://doi.org/10.1136/bmj.j5024
SGC is an R&D focused developer of nutraceutical and pharmaceutical gummy products. The company specializes in formulating Functional Gummy® products combining the wealth of the in-house knowledge in pharmaceutics, chemistry, western medicine and herbal medicine. The company provides performance gummies® inspired by Traditional Chinese Medicine including MOCCA SHOTS™, ENERGON QUBE™, FUNTIONAL FRUIT®, and SEATTLE BEAUTY®.
To learn more, visit https://seattlegummy.com
, email@example.com,call 206-257-0464, or join at https://seattlegummy.com/be-an-informed-member/